CAS Number51-98-9
Synonyms17α-Ethinyl-19-nortestosterone acetate; NORLUTATE; 17α-Ethynyl-19-nortestosterone acetate; 19-Norethindrone acetate; 17β-Acetoxy-19-nor-17α-pregn-4-en-20-yn-3-one; (17α)-3-Oxo-19-norpregn-4-en-20-yn-17-yl acetate; 19-Nor-17α-pregn-4-en-20-yn-3-one, 17-hydroxy-, acetate; 17-α-Ethynyl-19-nortestosterone acetate; 17α-Ethinyl-19-nortestosterone-17β-acetate; Milligynon; MFCD04039850; 17α-Ethynyl-17β-acetoxy-19-norandrost-4-en-3-one; 17-Acetoxy-19-nor-17α-pregn-4-en-20-yn-3-one; Norethindrone acetate; Norethisterone acetate; Primolut-Nor; 17-Hydroxy-19-nor-17α-pregn-4-en-20-yn-3-one acetate; EINECS 200-132-0; Norlutin A; 17-α-Ethinyl-19-nortestosterone-17-β-acetate; Norlutin acetate; 17α-Ethynyl-17-hydroxyestr-4-en-3-one acetate; Norethindrone 17-acetate; 17β-Hydroxy-19-nor-17α-pregn-4-en-20-yn-
Molecular FormulaC22H28O3
Molecular Weight340.467
Purity98%
Density1.1±0.1 g/cm3
Boiling Point454.7±45.0 °C at 760 mmHg
AppearanceSolid;White to Almost white powder to crystal
EINECS200-132-0
Symbol
Signal WordWarning
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 51-98-9 |
| Catalog No. | 2A-9008601 |
| Chinese Name | 醋酸炔诺酮 |
| Synonyms | 17α-Ethinyl-19-nortestosterone acetate; NORLUTATE; 17α-Ethynyl-19-nortestosterone acetate; 19-Norethindrone acetate; 17β-Acetoxy-19-nor-17α-pregn-4-en-20-yn-3-one; (17α)-3-Oxo-19-norpregn-4-en-20-yn-17-yl acetate; 19-Nor-17α-pregn-4-en-20-yn-3-one, 17-hydroxy-, acetate; 17-α-Ethynyl-19-nortestosterone acetate; 17α-Ethinyl-19-nortestosterone-17β-acetate; Milligynon; MFCD04039850; 17α-Ethynyl-17β-acetoxy-19-norandrost-4-en-3-one; 17-Acetoxy-19-nor-17α-pregn-4-en-20-yn-3-one; Norethindrone acetate; Norethisterone acetate; Primolut-Nor; 17-Hydroxy-19-nor-17α-pregn-4-en-20-yn-3-one acetate; EINECS 200-132-0; Norlutin A; 17-α-Ethinyl-19-nortestosterone-17-β-acetate; Norlutin acetate; 17α-Ethynyl-17-hydroxyestr-4-en-3-one acetate; Norethindrone 17-acetate; 17β-Hydroxy-19-nor-17α-pregn-4-en-20-yn- |
| Molecular Formula | C22H28O3 |
| Molecular Weight | 340.467 |
| Purity | 98 |
| Density | 1.1±0.1 g/cm3 |
| Boiling Point | 454.7±45.0 °C at 760 mmHg |
| Appearance | Solid;White to Almost white powder to crystal |
| Storage Condition | This product should be sealed and stored in a cool |
| Application | Norethindrone acetate is an FDA-approved progestin for the treatment of endometriosis, uterine bleeding caused by abnormal hormone levels, and secondary amenorrhea in women. |
| EINECS | 200-132-0 |
| HTC | 2915299090 |
| MDL Number | MFCD03225496 |
| SMILES | C#CC1(OC(C)=O)CCC2C3CCC4=CC(=O)CCC4C3CCC21C |
| InChI | InChI=1S/C22H28O3/c1-4-22(25-14(2)23)12-10-20-19-7-5-15-13-16(24)6-8-17(15)18(19)9-11-21(20,22)3/h1,13,17-20H,5-12H2,2-3H3/t17-,18+,19+,20-,21-,22-/m0/s1 |
| InChI Key | IMONTRJLAWHYGT-ZCPXKWAGSA-N |
| Hazard Symbols | Transport |
| Risk Codes | R40;R48 |
| Safety Description | S36/37 |
| MSDS | msds/8601_2_51_98_9.pdf |
| Bioactivity | Norethindrone acetate is a female progestin approved by FDA for the treatment of endometriosis, uterine bleeding caused by abnormal hormone levels, and secondary amenorrhea. Related Catalog Signaling Pathways >> Others >> Progesterone Receptor Research Areas >> Cardiovascular Disease Research Areas >> Endocrinology Research Areas >> Inflammation/Immunology Target Progesterone Receptor[1] In Vivo Norethindrone acetate could be a cost-effective alternative with relatively mild side effects in the treatment of symptomatic endometriosis. Subjects treated with norethindrone acetate obtain dysmenorrhea and noncyclic pelvic pain relief[1]. Norethindrone acetate alone is a well-tolerated, effective option to manage pain and bleeding for all stages of endometriosis. Post-Norethindrone acetate bleeding scores are improved regardless of prior hormonal regimen, and post-Norethindrone acetate pain scores improved in all patients except for those previously prescribed GnRH-agonist plus add-back[2]. Norethindrone acetate shows low acute toxicity in experimental animals and is consistent with the lack of toxicity seen in humans. Administration of norethindrone acetate alone to rodents at several multiples of the human dose results in no treatment related mortality, hematological changes, behavioral changes, or organ pathology[3]. Norethindrone acetate administration leads to significant and proportional reductions of the concentrations of triglycerides, cholesterol and phospholipids of plasma lipoproteins of density <1.006 of rats fed a high carbohydrate diet. Norethindrone acetate (0.1 mM) also significantly inhibits the incorporation of both palmitate and glycerol into triglycerides of isolated hepatocytes from fed rats[4]. Animal Admin Rats: Female Sprague-Dawley rats (200-210 g), 6 of which serve as controls, are individually caged in an animal room illuminated from 9:00 a.m. to 9:00 p.m. Each of the 7 rats receiving norethindrone acetate is fed 35 μg/day for 2 weeks. Water and the rat chow which is high in carbohydrate are available ad libitum[4]. References [1]. Muneyyirci-Delale O, et al. Effect of norethindrone acetate in the treatment of symptomatic endometriosis. Int J Fertil Womens Med. 1998 Jan-Feb;43(1):24-7. [2]. Kaser DJ, et al. Use of norethindrone acetate alone for postoperative suppression of endometriosis symptoms. J Pediatr Adolesc Gynecol. 2012 Apr;25(2):105-8. [3]. Maier WE, et al. Pharmacology and toxicology of ethinyl estradiol and norethindrone acetate in experimental animals. Regul Toxicol Pharmacol. 2001 Aug;34(1):53-61. [4]. Cheng DC, et al. Norethindrone acetate inhibition of triglyceride synthesis and release by rat hepatocytes. Atherosclerosis. 1983 Jan;46(1):41-8. Chemical & Physical Properties Density 1.1±0.1 g/cm3 Boiling Point 454.7±45.0 °C at 760 mmHg Molecular Formula C22H28O3 Molecular Weight 340.456 Flash Point 197.1±28.8 °C Exact Mass 340.203857 PSA 43.37000 LogP 3.99 Vapour Pressure 0.0±1.1 mmHg at 25°C Index of Refraction 1.556 InChIKey IMONTRJLAWHYGT-ZCPXKWAGSA-N SMILES C#CC1(OC(C)=O)CCC2C3CCC4=CC(=O)CCC4C3CCC21C Storage condition 2~8°C |
| Use of | Norethindrone acetate is a female progestin approved by FDA for the treatment of endometriosis, uterine bleeding caused by abnormal hormone levels, and secondary amenorrhea. Properties Articles34 Name norethisterone acetate Synonym More Synonyms 19-Norethindrone acetate Biological Activity Description Norethindrone acetate is a female progestin approved by FDA for the treatment of endometriosis, uterine bleeding caused by abnormal hormone levels, and secondary amenorrhea. Related Catalog Signaling Pathways >> Others >> Progesterone Receptor Research Areas >> Cardiovascular Disease Research Areas >> Endocrinology Research Areas >> Inflammation/Immunology Progesterone Receptor[1] References [1]. Muneyyirci-Delale O, et al. Effect of norethindrone acetate in the treatment of symptomatic endometriosis. Int J Fertil Womens Med. 1998 Jan-Feb;43(1):24-7. [2]. Kaser DJ, et al. Use of norethindrone acetate alone for postoperative suppression of endometriosis symptoms. J Pediatr Adolesc Gynecol. 2012 Apr;25(2):105-8. [3]. Maier WE, et al. Pharmacology and toxicology of ethinyl estradiol and norethindrone acetate in experimental animals. Regul Toxicol Pharmacol. 2001 Aug;34(1):53-61. [4]. Cheng DC, et al. Norethindrone acetate inhibition of triglyceride synthesis and release by rat hepatocytes. Atherosclerosis. 1983 Jan;46(1):41-8. Chemical & Physical Properties Molecular Formula C22H28O3 Exact Mass 340.203857 PSA 43.37000 Index of Refraction 1.556 InChIKey IMONTRJLAWHYGT-ZCPXKWAGSA-N |
| Tax Rebate | 9.0% |
| Supervision | A. Customs clearance form for inbound goods B. Customs clearance form for outbound goods |
| Inspection | R. Imported food hygiene supervision and inspection S. Export food hygiene supervision and inspection M. Imported commodity inspection N. Exported commodity inspection |
| Transport Info | Product name: Purity: 99.0% |
| MSDS Transport Info | Module 14. Shipping information 14.1 UN number European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.2 Names specified by the United Nations (UN) European Land Transport Dangerous Regulations: No dangerous goods IMDG Code: No dangerous goods International Air Transport Dangerous Regulations: No dangerous goods 14.3 Transport hazard categories European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.4 Package group European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.5 Environmental hazards European Land Transport Dangerous Regulations: No International Maritime Transport Dangerous Regulations Maritime Pollutants: No International Air Transport Risk Regulations: No 14.6 Special precautions for users No data available |
| Related Products in Specialty Chemicals | ||
|---|---|---|
| N-Methyl-N-[2-(4-nitrophenoxy)ethyl]-4-nitrophenylamine | 2A-108593 | 2A-9008593 |
| N-Methyl-N-1-naphthylamine | 2216-68-4 | 2A-9008594 |
| N-Methyl-N-phenylformamide | 93-61-8 | 2A-9008595 |
| N-Naphthalen-1-yl-formamide | 2A-108596 | 2A-9008596 |
| N-Octylglucamine | 23323-37-7 | 2A-9008599 |
| Novoldiamine | 140-80-7 | 2A-9008602 |
| N-Pentadecylpyridinium bromide | 53171-29-2 | 2A-9008603 |
| N-Phenylmethanesulfonamide | 1197-22-4 | 2A-9008604 |
| N-Phenyltetrafluorophthalimide | 116508-58-8 | 2A-9008605 |
| N-Vanillylamine hydrochloride | 7149-10-2 | 2A-9008611 |
| Browse all Specialty Chemicals products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS